ASTRA Therapeutics key facts
as of Oct 2026- Developer of an anti-parasite technology intended to provide therapies for parasitic diseases such as malaria.
- ASTRA Therapeutics is valued at approximately $28.0M as of Oct 2026 (last reported valuation).
- It has raised $9.7M; the latest was Later Stage VC ($9.7M) in Jul 2025.
- Notable investors include Venture Kick, Kickfund, Digitalis Ventures, Borealis Ventures, Gebert Rüf Foundation — 6 tracked in total.
- Status: Privately Held (backing).
ASTRA Therapeutics's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·Watch ASTRA Therapeutics: the Monday email on marks, rounds and moves
ASTRA Therapeutics funding rounds
No funding rounds for ASTRA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ASTRA Therapeutics
6ASTRA Therapeutics valuation
ASTRA Therapeutics's last reported valuation was $28 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
ASTRA Therapeutics investors
6 investors are on record for ASTRA Therapeutics, including Venture Kick, Kickfund, Digitalis Ventures and Borealis Ventures.
About ASTRA Therapeutics
Developer of an anti-parasite technology intended to provide therapies for parasitic diseases such as malaria. The company offers a technology to fight against a broad range of parasites with precision-engineered drugs, enabling individuals to get cures for parasitic diseases like malaria, cryptosporidiosis, and toxoplasmosis.
- Sector
- Healthcare
- HQ
- Villigen, Switzerland
- Founded
- 2019
- Employees
- 4
- Website
- astratherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.